Catalyst Reconciled Depreciation from 2010 to 2024

CPRX Stock  USD 15.62  0.14  0.89%   
Catalyst Pharmaceuticals Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation is likely to outpace its year average in 2024. During the period from 2010 to 2024, Catalyst Pharmaceuticals Reconciled Depreciation regression line of annual values had r-squared of  0.38 and arithmetic mean of  3,529,412. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2006-09-30
Previous Quarter
9.1 M
Current Value
9.4 M
Quarterly Volatility
2.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Catalyst Pharmaceuticals over the last few years. It is Catalyst Pharmaceuticals' Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Catalyst Reconciled Depreciation Regression Statistics

Arithmetic Mean3,529,412
Geometric Mean197,989
Coefficient Of Variation246.83
Mean Deviation5,715,310
Median45,689
Standard Deviation8,711,807
Sample Variance75.9T
Range25.5M
R-Value0.61
Mean Square Error51.1T
R-Squared0.38
Significance0.02
Slope1,193,163
Total Sum of Squares1062.5T

Catalyst Reconciled Depreciation History

202425.6 M
202324.4 M
20221.2 M
2021192 K
2020885.3 K
2019297.7 K
201838 K

About Catalyst Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Catalyst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Catalyst Pharmaceuticals investors use historical funamental indicators, such as Catalyst Pharmaceuticals's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Although Catalyst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Catalyst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Catalyst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation24.4 M25.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.